Loading clinical trials...
Loading clinical trials...
Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)
Conditions
Interventions
DCR-MYC
Locations
6
United States
Mayo Clinic
Scottsdale, Arizona, United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States
National University Hospital of Singapore
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Asan Medical Center
Seoul, South Korea
Start Date
January 27, 2015
Primary Completion Date
October 11, 2016
Completion Date
October 11, 2016
Last Updated
July 11, 2024
NCT06066138
NCT06811116
NCT06345508
NCT07485114
NCT04380545
NCT07291076
Lead Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions